Mandate

Vinge advises Cellink in directed new issues of shares of MSEK 946

Vinge has advised Cellink in connection with directed new issues of shares of approximately 5.9 million class B shares which will generate MSEK 946 for Cellink.

The subscription price has been set through a so‑called accelerating book building procedure performed by Carnegie and J.P. Morgan and corresponds to a discount of 1.7% compared to the share’s closing date rate on Nasdaq Stockholm. Almost 4.3 million shares have been issued by virtue of the authorization resolved by the general meeting and approximately 1.6 million shares have been issued conditional upon approval by an extraordinary general meeting. The purpose of the new issues of shares is, in part, financing of the cash element of the purchase price for the acquisition of Scienion Ag., and, in part, to create scope for Cellink’s continued M&A agenda.

Vinge’s team primarily consisted of Anders StridEdin Agic and Victoria Gunnerek.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025